Denosumab Biosimilar Authorization by EMA: Key Details
The EMA has authorized Denosumab biosimilars, marking a significant advancement in osteoporosis treatment and improving patient access to effective therapies.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: April 01, 2026
The European Medicines Agency (EMA) has granted marketing authorization to the first biosimilar of denosumab, marking a significant step in expanding treatment options for osteoporosis within the European Union. This EMA denosumab biosimilar approval is expected to enhance treatment accessibility and reduce costs by offering a more affordable alternative to the reference product for patients across the EU.
Drug Overview
Denosumab is a fully human monoclonal antibody that belongs to the class of RANKL inhibitors. Its mechanism of action involves binding to RANKL (receptor activator of nuclear factor kappa-B ligand), preventing its interaction with RANK on osteoclasts. This action inhibits osteoclast-mediated bone resorption, thereby increasing bone mass. The reference product, Prolia®, is widely used for the treatment of osteoporosis and fracture risk reduction in postmenopausal women and other at-risk populations.
Clinical Insights
Biosimilars of denosumab undergo rigorous comparability exercises to demonstrate similarity in efficacy, safety, and immunogenicity to the reference product. These exercises include analytical, preclinical, and clinical studies. The EMA's biosimilar approval pathway emphasizes the totality of evidence, including pharmacokinetic/pharmacodynamic equivalence and at least one clinical efficacy trial.
Regulatory Context
The EMA's biosimilar approval process typically involves the submission of a comprehensive dossier including quality, non-clinical, and clinical data. The review process can take approximately 210 days, excluding any clock stops for applicant responses. Post-authorization, mandatory pharmacovigilance and risk management plans are put in place to monitor long-term safety.
Market Impact
The introduction of denosumab biosimilars is anticipated to enhance market competition, potentially lowering treatment costs and improving patient access in the EU. The osteoporosis treatment market in the EU includes established biologics like denosumab and bisphosphonates, serving a large patient population primarily of postmenopausal women at high fracture risk and men with osteoporosis. As a biosimilar, this product offers comparable efficacy and safety to the reference denosumab product (Prolia®) but at a potentially lower cost, increasing affordability and uptake.
Future Outlook
The availability of denosumab biosimilars may lead to increased focus on optimizing treatment strategies and exploring combination therapies for osteoporosis management. The increased affordability may also support broader adoption of denosumab in patient populations where cost has been a barrier.
Frequently Asked Questions
What is a denosumab biosimilar?
A denosumab biosimilar is a medication that is highly similar to the reference denosumab product (Prolia®) in terms of safety, efficacy, and immunogenicity. It offers a more affordable alternative for treating osteoporosis.
How does denosumab work?
Denosumab works by binding to RANKL, a protein that promotes bone resorption. By blocking RANKL, denosumab reduces bone breakdown and increases bone density.
What are the expected benefits of denosumab biosimilars?
The primary benefits include increased market competition, reduced treatment costs, and improved patient access to osteoporosis treatment in the EU.
References
References
- European Medicines Agency. EMA approval. Accessed 2026-04-01.
European Regulatory Correspondent
Dr. Marcus Weber is a cardiologist and former EMA rapporteur with expertise in European pharmaceutical policy. He holds degrees from Heidelberg University and has advised on over 50 marketing authoriz...
About the Author
Related Articles
FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Receives Key Diabetes Drug Approval
Biosimilar Uptake EU: Market Impact Post-Patent Expirations & HTA Regulation
EU Pharmaceutical Legislation Reform: Impact on Generics & Biosimilars 2026-27
